Eclipse Therapeutics, Inc., a San Diego, California-based biotechnology company dedicated to the discovery and development of therapeutics that target cancer stem cells and other forms of innovative cancer treatment, closed an up to $2m seed financing.
The round was led by founding investor City Hill Ventures, LLC.
The company intends to use the proceeds from this first close to launch operations.
In conjunction with the financing, Jonathan Lim, M.D., of City Hill Ventures, has joined the Board of Directors as Executive Chairman.
Founded in March of 2011 by CEO Peter Chu, Ph.D., Christopher Reyes, Ph.D. (Eclipse Therapeutics, Inc.), and Jonathan Lim, Eclipse is discovering therapeutic antibodies that specifically target key biologic pathways critical to the activity and survival of cancer stem cells.